Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited announced that its Co-Founder and CEO, John Konstantopoulos, will present at the Bell Potter Healthcare Conference 2025. This virtual event, which brings together industry leaders and investors, will showcase Artrya’s advancements in AI-powered cardiac care solutions, potentially enhancing the company’s visibility and positioning in the healthcare industry.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. The company is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 1,030,691
Technical Sentiment Signal: Buy
Current Market Cap: A$564.4M
For a thorough assessment of AYA stock, go to TipRanks’ Stock Analysis page.